诺唯赞创新性地研发出高灵敏血液检测产品，率先突破传统检测手段的局限性，以微创、便捷、经济的 特点，为AD的早期筛查、诊断及预后评估提供了高效工具。其已获批的AD血液生物标志物检测试剂产 品，包含多项独家核心指标，是我国基于化学发光平台通过血液样本检测AD核心生物标志物获证数量 较多的试剂厂商，也是全球范围内率先实现p-tau217指标检测商业化的企业。学术界普遍认为，p- tau217是AD早期诊断和鉴别诊断中极具潜力的生物标志物，其精准检测能力的商业化，将极大提升AD 诊断的准确性和前瞻性。 随着中国老龄化程度加剧，应对老龄化的社会行动已进入加速期。在众多老年健康挑战中，阿尔茨海默 病（以下简称AD）是常见的隐匿性神经退行性疾病，是导致老年人认知障碍和记忆丧失的主要原因。 我国现有约1700万AD患者，而临床确诊时多数已进入中晚期。在此关键时间节点，早筛技术的突破为 破解AD防治困局带来新曙光——今年9月，国内生物科技企业诺唯赞（SH.688105）一次性获批7项神经 系统血液检测试剂盒，产品覆盖AD、帕金森病（PD）等神经系统疾病的早期诊断，其中MTBR-tau243 等5项生物标志物指标填补行业空白，为 ...

Core Insights - A new blood testing tool named "HPV-DeepSeek" developed by scientists at Massachusetts General Hospital can identify HPV-related head and neck cancers up to 10 years before symptoms appear, potentially improving patient outcomes and quality of life [1][2] - In the U.S., 70% of head and neck cancers are caused by HPV, with incidence rates rising annually. Unlike cervical cancer, there are currently no screening methods for HPV-related head and neck cancers, leading to late diagnoses [1] - The "HPV-DeepSeek" method utilizes whole genome sequencing to detect trace amounts of HPV DNA fragments shed from tumors into the bloodstream, achieving 99% specificity and sensitivity in clinical applications, surpassing existing detection methods [1] Research Findings - In a study involving 56 samples from the Brigham Biobank, "HPV-DeepSeek" detected HPV tumor DNA in 22 out of 28 cancer patients, with the earliest positive sample collected 7.8 years before diagnosis. All control samples tested negative, indicating high specificity [2] - By incorporating machine learning techniques, the research team improved detection sensitivity to identify 27 out of 28 cancer cases, including samples collected up to 10 years prior to diagnosis [2] - Further research is underway using hundreds of samples collected from the National Cancer Institute's screening trials for prostate, lung, colorectal, and ovarian cancers to validate these findings [2]